140 related articles for article (PubMed ID: 25655637)
21. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
22. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
23. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
24. The impact of 18F-FDG PET/CT in patients with liver metastases.
Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766
[TBL] [Abstract][Full Text] [Related]
25. [Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein].
Chen Z; Liang H; Zhang X; Wang X; Chen W; Shi X; Yi C; Rao L
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1615-9. PubMed ID: 23174588
[TBL] [Abstract][Full Text] [Related]
26. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
27. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
28. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
30. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
31. Three-Dimensional Image Fusion of
Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
[TBL] [Abstract][Full Text] [Related]
32. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
[TBL] [Abstract][Full Text] [Related]
34. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
36. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
Chiewvit S; Jiranantanakorn T; Apisarnthanarak P; Kanchaanapiboon P; Hannanthawiwat C; Ubolnuch K; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
[TBL] [Abstract][Full Text] [Related]
37. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
39. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
40. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
